Getein Biotech

Getein Biotech Inventory

The Inventory of Getein Biotech (603387.SS) as of Nov 5, 2026 is 183.83 M CNY. In the previous year, Inventory was 194.46 M CNY — a change of -5.47% (lower).

Inventory

183.83 MCNY

YoY

-5.47%

Last updated:

Inventory of Getein Biotech is 2025 183.83 M CNY. Inventory of Getein Biotech was 2024 194.46 M CNY. It decreases by -5.47% lower compared to the previous year.

The Getein Biotech Inventory history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Inventory
Date
Inventory
Jan 1, 2018
126.38 M CNY
Jan 1, 2019
160.68 M CNY
Jan 1, 2020
211.99 M CNY
Jan 1, 2021
252.30 M CNY
Jan 1, 2022
269.39 M CNY
Jan 1, 2023
229.71 M CNY
Jan 1, 2024
194.46 M CNY
Jan 1, 2025
183.83 M CNY
The Getein Biotech Inventory history
YEARInventoryYoY
183.83 MCNY-5.47%
194.46 MCNY-15.35%
229.71 MCNY-14.73%
269.39 MCNY+6.77%
252.30 MCNY+19.02%
211.99 MCNY+31.93%
160.68 MCNY+27.15%
126.38 MCNY+102.87%
62.29 MCNY+26.99%
49.05 MCNY+24.59%
39.37 MCNY+95.06%
20.18 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Getein Biotech Stock analysis

What does Getein Biotech do? Getein Biotech Inc generates revenue through the sale of in vitro diagnostic reagents and diagnostic instruments. The company offers POCT reagents, chemiluminescence reagents, biochemical reagents, blood cell reagents, and hemagglutination reagents. Diagnostic instruments include the FIA 8000 and FIA 8600 immunoquantitative analyzers, Getein 1100 and Getein 1180 fluorescence immunoquantitative analyzers, CM 400 automatic biochemical analyzer, MAGICL 6000 automatic chemiluminescence analyzer, and BHA-5000 five classification blood cell analyzer. The firm also provides testing and agency services. Products are distributed domestically and to overseas markets. The primary buyers of Getein Biotech's products include healthcare facilities, laboratories, and medical institutions within China and international markets. Domestic sales focus on the Chinese healthcare sector, while overseas markets extend to global customers seeking diagnostic solutions. The company's reagent and instrument portfolio targets hospitals, clinics, and diagnostic centers requiring reliable testing equipment and consumables. Getein Biotech's revenue streams are derived from direct sales of its diagnostic reagents and instruments, as well as service-based offerings like testing and agency services. The company's product range caters to both domestic and international healthcare providers, with a strong emphasis on in vitro diagnostic solutions for blood analysis, chemiluminescence, and biochemical testing. The firm's distribution strategy ensures its products reach medical facilities across China and internationally. Getein Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Getein Biotech stock

Inventory of Getein Biotech is 183.83 M CNY in 2025.

Inventory of Getein Biotech changed from 194.46 M CNY to 183.83 M CNY, representing a -5.47% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Inventory Getein Biotech since 2006 – with annual values, charts, and detailed analysis.

Inventory includes raw materials, work-in-progress, and finished goods. Efficient inventory management is crucial for profitability.

Inventory's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Inventory's Getein Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Getein Biotech

All Key Metrics — Getein Biotech